INO vs. CERS, ATRC, PLSE, SILK, EMBC, CATX, ATRI, KIDS, FNA, and SIBN
Should you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Cerus (CERS), AtriCure (ATRC), Pulse Biosciences (PLSE), Silk Road Medical (SILK), Embecta (EMBC), Perspective Therapeutics (CATX), Atrion (ATRI), OrthoPediatrics (KIDS), Paragon 28 (FNA), and SI-BONE (SIBN). These companies are all part of the "surgical & medical instruments" industry.
Cerus (NASDAQ:CERS) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.
In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 2 mentions for Cerus. Inovio Pharmaceuticals' average media sentiment score of 0.93 beat Cerus' score of 0.18 indicating that Cerus is being referred to more favorably in the media.
78.4% of Cerus shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 3.4% of Cerus shares are owned by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cerus has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Cerus currently has a consensus target price of $3.83, suggesting a potential upside of 61.06%. Inovio Pharmaceuticals has a consensus target price of $56.75, suggesting a potential upside of 401.33%. Given Cerus' higher possible upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Cerus.
Inovio Pharmaceuticals received 149 more outperform votes than Cerus when rated by MarketBeat users. However, 72.26% of users gave Cerus an outperform vote while only 71.41% of users gave Inovio Pharmaceuticals an outperform vote.
Cerus has a net margin of -19.27% compared to Cerus' net margin of -16,238.91%. Inovio Pharmaceuticals' return on equity of -58.65% beat Cerus' return on equity.
Cerus has higher revenue and earnings than Inovio Pharmaceuticals.
Summary
Cerus beats Inovio Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Inovio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inovio Pharmaceuticals Competitors List
Related Companies and Tools
Free INO Stock Alerts